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Background: Ovarian granulosa cell tumors (GCTs) are the most frequent sex cord-stromal tumors. Several studies
have shown that a somatic mutation leading to a C134W substitution in the transcription factor FOXL2 appears in
more than 95% of adult-type GCTs. Its pervasive presence suggests that FOXL2 is the main cancer driver gene.
However, other mutations and genomic changes might also contribute to tumor formation and/or progression.
Methods: We have performed a combined comparative genomic hybridization and transcriptomic analyses of 10
adult-type GCTs to obtain a picture of the genomic landscape of this cancer type and to identify new candidate
co-driver genes.
Results: Our results, along with a review of previous molecular studies, show the existence of highly recurrent
chromosomal imbalances (especially, trisomy 14 and monosomy 22) and preferential co-occurrences (i.e. trisomy
14/monosomy 22 and trisomy 7/monosomy 16q). In-depth analyses showed the presence of recurrently broken,
amplified/duplicated or deleted genes. Many of these genes, such as AKT1, RUNX1 and LIMA1, are known to be
involved in cancer and related processes. Further genomic explorations suggest that they are functionally related.
Conclusions: Our combined analysis identifies potential candidate genes, whose alterations might contribute to
adult-type GCT formation/progression together with the recurrent FOXL2 somatic mutation.
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Ovarian granulosa cell tumors (GCTs) are the most
frequent sex cord-stromal tumors, and account for more
than 5% of ovarian cancers [1]. Two different forms,
juvenile and adult, have been described based on the age
of onset and histopathological features [2]. GCTs tend to
be low-grade malignancies, but can recur up to 40 years
after primary tumor resection [3]. Various studies have re-
vealed that a somatic mutation leading to the p.C134W
substitution in the transcription factor FOXL2 appears
in > 95% of adult-type GCTs [4].
Transactivation studies have suggested that the p.C134W
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unless otherwise stated.FOXL2 with SMAD3 [5] and FOXL2 activity in other sys-
tems [6]. This variant is also deficient in its ability to pro-
mote apoptosis [7] and displays a mild loss-of-function on
targets involved in cell cycle and DNA-damage repair [8].
We have recently performed a transcriptomic profiling
of 10 human adult-GCTs and ethnically-matched GC
controls. This study showed that GCTs display several
typical hallmarks of cancer. For instance, among FOXL2
direct targets, we detected an up-regulation of genes as-
sociated with cell cycle control and a down-regulation of
genes related with apoptosis [9]. The pervasive somatic
FOXL2 mutation is expected to be the main driver of
GCTs. However, we hypothesize that it might engender
or be accompanied by other mutations and genomic
changes that might facilitate tumor formation and/or
progression. Here, we have explored this possibility by
performing a comparative genomic hybridization (CGH)l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation with their transcriptomes. This combined analysis
is the first attempt to obtain a “bird’s eye” view of the
genomic landscape of this cancer type and to identify new
candidate (co-)driver genes (termed henceforth driver
genes for simplicity).
Methods
Ethics statement
This research involves human samples and has been
performed with the approval of the Ethics Committee
of the Helsinki University Central Hospital. Research
was carried out in compliance with the Helsinki
Declaration.
Comparative Genomic Hybridization (CGH)
The CGH was performed using genomic DNA from
the tumor samples co-hybridized with an equimolar
mix of 10 ethnically-matched (finnish) DNA samples
on NimbleGen 12x135K CGH arrays, which 60-mer
probes spaced every 13 kb on average. Sample pro-
cessing, hybridization and data acquisition were per-
formed at Nimblegen according to an in-house
standard protocol. CGH microarray data are available
in the ArrayExpress database (www.ebi.ac.uk/arrayex-
press) under accession number E-MTAB-2873. CGH
data were analyzed as log2 values of the ratio be-
tween the fluorescences of tumor and reference gen-
omic DNA samples, using MeV software (TM4 suite,
http://www.tm4.org).
CGH and transcriptome correlations
For large-scale alterations, the CGH data were aver-
aged for sliding windows of 130 kb over the relevant
chromosomes. For the transcriptomic data, we used
our previously published data from the 10 tumors, as
described in [9] (NimbleGen Human Expression 12 ×
135 K array set, accession E-MTAB-483 in the
ArrayExpress database). The two independent tran-
scriptomic hybridizations were averaged for each tran-
script, and then we computed the average expression
levels for each gene.
To better measure the impact of large-scale gen-
omic alterations on gene expression we divided the
expression values for genes located within aneuploid
regions by their mean expression in the tumors with-
out the analyzed alteration. Expression ratios above/
below 1 in the natural scale (or above/below 0 in
log2 scale) in aneuploid regions are suggestive of a
“correlation” between genomic duplications/deletions
and gene expression. Finally, these ratios were aver-
aged for 30 windows (of equal size) per chromosome.
The CGH and transcriptomic profiles were displayed
using MeV software.To identify candidate drivers, we used the combination
of several criteria. First, we aimed at identify genes with
an expression correlated to small-scale imbalances. For
this, the CGH probes, amplified/duplicated or deleted in
at least 50% of the cells (which corresponds to log ratio
of 0,322 or −0,415, respectively) and in at least two
tumors, were identified using MeV software. Next, genes
were retained for further analysis if one or several ampli-
fied/deleted CGH probe(s) mapped within 25 kb of the
gene coordinates. Given the 13 kb-resolution of the
CGH chip, a 25-kb maximum spacing enabled us to
detect all relevant genes. Furthermore, transcriptomic
values had to be significantly correlated with the
CGH data over all the tumors (Pearson correlation
coefficient, R). The threshold of statistical significance
used for R was determined considering that, for a
sample size N, with observed values of R, there is a
statistic t such that:
t ¼ R
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n−2
1−R2
r
which follows approximately a Student-t distribution
with N-2 degrees of freedom. Application of this formula
to any particular observed value of R will test the null
hypothesis that the observed value comes from a popu-
lation in which the correlation between the two variables
is 0. For a sample size of N = 10 (all tumors in our co-
hort), the R that can be considered as statistically signifi-
cant according to this test is 0.63. In order to exclude
any effect of large-scale imbalances (such as trisomies or
monosomies), the gene-centered CGH/expression corre-
lations were computed in the relevant genomic regions
only for tumors without the large-scale imbalances.
Therefore, we adjusted the threshold for R significance
accordingly, to R > = 0.67 for 9 samples, R > = 0.71 for 8
samples and R > = 0.76 for 7 samples. Due to the small
sample size of our cohort, we could not apply a correc-
tion for multiple testing, such as Bonferroni’s or
Benjamini-Hochberg’s. Candidate driver genes were
further selected when i) being completely included in
the genomic alteration (i.e. fully amplified or deleted)
and ii) not being included in frequent CNVs in healthy
individuals, as defined by the Database of Genomic Vari-
ants (DGV, http://dgv.tcag.ca/dgv/app/home, as of 31/05/
2013).
Recurrently broken genes were identified by the exist-
ence, in at least 2 tumors, of one or several closely map-
ping breakpoints defined by amplifications/deletions
upstream and downstream, within the relevant gene. We
excluded genes for which the breakpoints mapped near
or within frequent CNVs according to DGV. This step
was necessary because the control DNA used for CGH
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not the somatic DNA from the respective patients.
Expressional correlation, protein interactor sharing and
transcriptomic neighbors sharing between candidate
drivers
Hierarchical clustering of the expression levels of broken,
amplified or deleted candidate drivers and FOXL2 was
performed with the MeV software, using complete linkage
and the Pearson correlation coefficient as a measure of
similarity.
For each candidate driver and FOXL2, two sets of tran-
scriptomic neighbors were defined by a statistically signifi-
cant correlation of expression in all tumors (R > = 0.63 or
R < = −0.63). These gene sets were analyzed using the
Enrichr tool (http://amp.pharm.mssm.edu/Enrichr [10]).
The extensive sharing of transcriptomic neighbors be-
tween the candidate drivers or FOXL2 was displayed using
Cytoscape 3.0.1 software, keeping only the strongly corre-
lated transcriptional neighbors (R > = 0,90) for clarity. The
network was built using the “prefuse force directed” algo-
rithm with EdgeBetweenness criteria, then manually edi-
ted for clarity.
Results and discussion
CGH of ovarian GCTs shows recurrent chromosomal
imbalances
To identify DNA copy number changes in GCTs, we
performed a CGH analysis of 10 tumor genomic DNA
samples, using microarrays. All the tumors bear the
FOXL2 somatic mutation C134W. Four tumors (H1, H8,
H28 and H30) did not display any large-scale genome al-
terations. However, there was no obvious correlation be-
tween the absence of imbalances and tumor stage, size
or age of occurrence. On the other extreme, the most al-
tered tumor was H4, which is not surprising, owing to
the fact that it is a recurrence (Additional file 1: Table S1a
and S1b).
The detected large-scale imbalances were either recurrent
or appeared only once in our samples. Whole-chromosome
alterations involved trisomies 8 (1/10) and 14 (2/10), and
monosomies 16 (1/10), 21 (2/10) and 22 (3/10). Other
long-range changes included duplication of 1p11.1-qter
(H4), and deletions of 1p11.1-p22.1 (H33), 12q13.11-
q13.13 (H4), 13q13.3-q32.1 (H4), 16p11.2-qter (H4). Our
analysis combined with a review of the literature ([11-14])
compiles the data of 94 adult-type GCTs (Figure 1 and
Additional file 1: Table S1c). 64 of them presented large-
scale alterations. This compilation shows the existence
of highly recurrent chromosomal alterations, such as super-
numerary chromosomes 8, 9, 12 and especially chromo-
some 14 (n = 25/64, for the latter) and partial or complete
loss of chromosomes 1p, 13q, 16, 21 and particularly 22
(n = 34/64, for the latter). The compiled data also showthe co-occurrence of chromosomal alterations, i.e. -1p/-22
(n = 5); +7/-16q (n = 5); +12/-22 (n = 6); −13q/-22 (n = 4);
+14/-22 (n = 18). However, only the +14/-22 and the +7/-
16q associations were non-random (p = 0,02 and p =
0,001, respectively, according to a two-tailed Fisher’s exact
test). This suggests that the co-occurrence of +14/-22
and +7/-16q imbalances should confer a selective advan-
tage, whose molecular basis remains to be elucidated.
Concerning the FOXL2 locus, all tumors have kept the
two alleles, although in two cases the DNA sequence
displayed only the presence of the mutated version (data
not shown). This can be due to either a second muta-
tional hit or a gene conversion event that provides a se-
lective advantage over heterozygous cells, as previously
noted [14].
Large-scale genomic alterations and their transcriptomic
translation
Next, we focused on the genes involved in the altered
chromosomal segments and compiled their expression
levels. Here, two transcriptomic hybridizations for the
same tumor were combined and the average expression
level for each gene was computed. Figure 2a shows that
gene expression levels averaged over Mb-sized windows
closely reflected the underlying chromosomal imbal-
ances, as detected by CGH.
To further explore the influence of DNA copy number
on gene expression, we compared the average expression
of genes located in altered segments with that of genes
located outside. For example, the copy number increased
from 1.01 for the non-amplified segment of chromo-
some 1 in tumor H4 to 1.35 for the amplified region
(Figure 2b). Consistently, the normalized gene expres-
sion averaged over the non-duplicated segment was 0.99
versus 1.21 for the duplicated region. A similar concord-
ance was observed for other amplifications and deletions
(Figure 2b and data not shown). Although there was a
correlation between DNA amounts and mRNA levels,
the degree of gene up- or down-regulation was always
slightly lower. Although this effect might be due, in
some cases, to contamination of tumor RNA with the
transcriptome of neighboring normal cells, this explan-
ation cannot apply to all samples. Thus, one is tempted
to argue that some degree of expression compensation to
chromosome dosage changes is taking place. Indeed, buffer-
ing of gene expression in response to genomic alterations
have been reported in Drosophila harboring chromosomal
imbalances [15-17], for human trisomy 21 [18] and for
genes included in Copy-Number Variants (CNVs) [19].
Identification of putative drivers: recurrently broken,
amplified/duplicated or deleted genes
To further exploit our CGH and transcriptomic data, we
focused on small-scale rearrangements that might help
Figure 1 Recurrent chromosomal imbalances in adult-type ovarian GCTs. The CGH was performed using genomic DNA from the tumor
samples co-hybridized with an equimolar mix of 10 ethnically-matched (finnish) DNA samples. Each chromosomal ideogram is depicted with
amplifications in red (on the left) and deletions in green (on the right). This compilation includes data from 94 adult-type GCTs from 5 studies,
among which 64 contain large-scale alterations. Smallest Regions of Overlaps (SROs), defined when several independent rearrangements point to
a common altered genomic region, are likely to contain driver genes involved in tumor progression. Here, SROs are indicated (black horizontal
lines) when they involve at least 5 imbalances of the same type (either amplifications or deletions). Details of chromosomal imbalances and
co-occurrences identified by the five studies are provided in Additional file 1: Table S1c.
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or breakage might be involved in tumorigenesis. First,
we aimed at identifying amplified or deleted candidate
drivers by combining GCH and transcriptomics. For this
purpose, we generated a list of amplified or deleted CGH
probes, whose log-ratio corresponded to at least 50% of
the cells harboring a heterozygous duplication or deletion,
in at least two tumors. Then, we computed the correlation
coefficient (R) over all tumors between the CGH values
and the mRNA expression values for the genes whose
boundaries mapped at less than 25 kb from a copy-
number-altered probe. This correlation filter was essential
because a local genomic alteration does not necessarily
imply a transcriptomic change. Thus, a meaningful driver,
mapping to an amplified/deleted region, should display a
reasonable correlation between copy number and mRNA
expression. We set the threshold for statistical significance
of Pearson’s correlation coefficient R to 0.63, which is the
standard cut-off for ten samples. Genomic regions in-
volved in large-scale imbalances such as trisomies ormonosomies were analyzed separately by removing data
from trisomic or monosomic tumors. For these regions,
the threshold for R was adjusted to 0.67 or 0.71 in
cases when 1 or 2 samples were removed. After ex-
cluding genes located within CNVs, we obtained a list of
48 candidates. After manual verification, we retained
13 amplified and 7 deleted genes fully located within the
imbalances. Tumors harbored alterations ranging from 2
to 9/13 amplifications and from 1 to 7/7 deletions
(Additional file 2: Table S2a).
A literature search shows the known or plausible im-
plication in tumorigenesis for most of these 20 candidates
(Table 1). AKT1, encoding a proto-oncogenic kinase, was
the most frequently amplified gene (6/10 tumors). AKT1
amplifications have been described in various types of
cancer [20-22]. The second most frequently amplified
gene (5/10 tumors) encodes the nuclear receptor NR1D1,
a survival factor in a subset of breast cancers. Its driver ef-
fect might rely on its antiapoptotic activity [23] or on its
known upregulation of genes involved in an abnormal
Figure 2 Transcriptomic effects of large-scale genomic rearrangements in adult-type GCTs. a. The CGH data (ratios tumor/reference) are
displayed as log2 values averaged for sliding windows of 130 kb over the relevant chromosomes. For the transcriptomic data, we first computed the
average expression levels for each gene (data from two transcriptomic hybridizations). Then we normalized gene expression as described in Methods.
Normalized expression values were averaged over 30 windows (of the same size) per chromosome. Notice the close “correlation” between the
chromosome copy-number and the expression levels of the genes involved in the imbalances. b. Comparison of the mean CGH values (ratios tumor/
reference, in the natural scale) for the amplified Chr1q in H4 or the deleted segment of Chr1 in H33 with respect to the rest (non imbalanced) of the
chromosome. For the transcriptome, the means of the normalized expression levels for genes located in altered segments (according to CGH) were
significantly different from the means for genes located outside on the same chromosome (using both a t-test and a Mann–Whitney non-parametric test).
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amplified in 4 out of 10 tumors, encodes the enzyme
catalyzing the final step for conversion of vitamin
B(12) into adenosylcobalamin. Interestingly, chemical
derivatives of adenosylcobalamin are used to image
breast, lung, colon, thyroid, and sarcomatous malig-
nancies [25]. TSPAN32, amplified in 3/10 tumors, en-
codes a member of the tetraspanin superfamily, and
is known to regulate cell proliferation. Along similar
lines, another candidate encodes TENC1 (amplified in
2/10 tumors), known to stimulate PI3K/Akt signaling.
Furthermore, TENC1 knock-down decreases cell pro-
liferation and its overexpression is associated with ag-
gressive hepatocellular carcinoma [26,27]. This points
to a deregulation of the PI3K/AKT pathway in GCTs,that would participate to tumorigenesis [28,29]. An-
other amplified candidate driver (3/10 tumors) en-
codes RANBP1, a cytoplasmic component of the
nuclear pore complex. RANBP1 ensures cargo release
from CRM1 upon export of specific mRNAs depend-
ing on the oncogenic factor eIF4E [30]. It is worth
noting that these last two genes, along with 4 other
amplified candidates, were found deleted in one
tumor, H4, which was the only recurrence included in
our samples.
Among the recurrently deleted genes, HSPA4, deleted
in 3 of the tumors, encodes a chaperone of the HSP110
family, predominantly expressed in the ovary [31]. Inter-
estingly, HSPA4 is known to regulate cell migration,
both positively and negatively [32,33]. The second gene
Table 1 Candidate driver genes identified as amplified or deleted in OGCTs, with correlated expression
Chr Gene # of tumors with Function & Implication in cancer if known Ref
Amp Del
14 AKT1 6 0 Known oncogenic kinase, core of one of the most frequently activated survival pathways in human cance. [50]
17 NR1D1 5 0 Ligand-sensitive transcription factor, regulates the expression of core clock proteins; required for survival
and proliferation of breast cancers
[24]
12 MMAB 4 0 catalyzes the final step for conversion of vitamin B(12) into adenosylcobalamin. Derivatives of the latter
are used to image breast, lung, colon, thyroid, and sarcomatous malignancies.
[25]
11 TSPAN32 3 0 Membrane protein, regulates T cell proliferative responses. Tetraspanins are implicated in various steps
of tumorigenesis.
[51]
11 CTSW 2 0 cysteine proteinase up-regulated in Large granular lymphocyte leukemia [52]
12 DGKA 2 0 converts DAG into PA, a second messenger activating multiple signaling pathways implicated in
tumorigenesis (i.e. mTOR signaling)
[53]
22 RANBP1 3 1* Soluble component of the nuclear pore complex. Oncogenic overexpression of eIF4E induces
overexpression of RANBP1
[30]
22 TRMT2A 3 1* cell-cycle regulated protein, one of the 5 immunohistochemical markers in the Mammostrat test used
to stratify breast cancers
[54]
12 TENC1 2 1* Promotes PI3K/Akt signaling, KD = > decreased proliferation. High expression associated with aggressive
hepatocellular carcinoma
[26]
16 PIEZO1 2 1* transmembrane protein involved in mechanotransduction. Mediates integrin activation by recruiting
R-Ras to the ER, modulating cell adhesion
[55]
12 SPRYD3 2 1* SPRY domain containing 3. Not studied na
22 C22orf26 3 2* Not studied - now named PRR34, proline rich 34 na
22 FAM19A5 3 2 postulated to function as brain-specific chemokines or neurokines, acting as regulators of immune and
nervous cells.
[56]
1 NVL 1* 3 AAA-ATPase, hTERT binding, essential for telomerase assembly. A nucleolar isoform is a component of
pre-ribosomal particles
[36]
19 C19orf18 0 2 not studied. Identified as significantly binding to oligomeric β-amyloid [57]
14 FAM177A1 0 2 Unknown function. Down-regulated by microRNA124 during neurogenesis. Identified as a target of
the E3 ubiquitin-ligase FANCA.
[58]
12 LIMA1 0 2 Inhibits actin depolymerization and cross-links filaments in bundles. Putative suppressor of
epithelial-mesenchymal transition and metastasis
[40]
17 TADA2A 0 2 transcriptional activator adaptor, in the PCAF and ATAC histone acetylase complexes, mediates DNA
damage-induced apoptosis and G1/S arrest
[44]
5 HSPA4 0 3 Heat shock chaperone of the HSP110 family. Regulates cell proliferation and G1/S progression by
releasing transcription factor ZONAB from tight junction sequestration
[59]
15 RTF1 0 3 part of the Paf1/RNA polymerase II complex, key regulator of transcription-related processes and
cell-cycle progression
[34]
*These genes were found altered in the opposite way in the tumor H4, the only recurrent tumor in our cohort.
Table 2 Genes identified as broken in OGCTs
Chr Gene Function & Implication in cancer if known Ref
8 C8orf34 cAMP-dependent protein kinase regulator.
Associated with irinotecan-related toxicities
in patients with non-small-cell lung cancer.
[60]
18 CELF4 CELF/BRUNOL protein, alternative splicing factor.
When lost, independent prognostic indicator in
colorectal cancer.
[61]
14 NPAS3 Basic helix-loop-helix and PAS domain-containing
transcription factor, tumor suppressor in astrocytomas
[62]
15 SPG11 Potential transmembrane protein phosphorylated
upon DNA damage. Mutated in recessive
hereditary spastic paraplegia.
[63]
21 RUNX1 CBF transcription factor subunit. Tumor suppressor,
with oncogenic fusions in leukemias and mutations
in breast cancers.
[64]
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the Paf1 complex, which is a key regulator of RNA poly-
merase II transcriptional activity and of cell-cycle pro-
gression. RTF1 is critical for histone and chromatin
modifications and telomeric silencing [34,35]. Another
link with telomere maintenance is NVL, also found de-
leted in 3 tumors. NVL encodes an AAA-ATPase essential
for hTERT binding and telomerase assembly [36]. In
addition, a nucleolar isoform of NVL participates in ribo-
some biosynthesis [37]. LIMA1 (a.k.a. EPLIN, Epithelial
protein lost in neoplasm), deleted in 2/10 OGCTs, en-
codes a metastasis suppressor, frequently lost in cancer
cells [38,39]. Consistently, it acts as a negative regulator
of epithelial-mesenchymal transition and invasiveness
[40] and its expression is inversely correlated with the
aggressiveness of breast cancer [41]. Another interesting
Caburet et al. BMC Cancer  (2015) 15:251 Page 7 of 11deleted gene, TADA2A, encodes an adaptor subunit of the
PCAF and ATAC histone acetylase complexes. TADA2A-
containing PCAF complex is essential for DNA-damage-
induced acetylation of p53, necessary to promote cell cyclea
b
Figure 3 Functional relationships between broken, amplified and del
of the expression levels of the 5 broken genes (purple), 13 amplified (red),
details in Methods). The clustering defines three groups of genes. The first
of broken genes, amplified MMAB and FOXL2. The second group includes a
Amplified TSPAN32 (anti-correlated to other amplified genes) defines a sepa
interaction network involving the proteins encoded by broken, amplified o
interactions were retrieved automatically by DAPPLE v2.0 (http://www.broa
parameters. The network was manually reorganized to highlight the expec
partners in signaling and transcription regulation. Gene set enrichment ana
network (the displayed p-values are Bonferroni-corrected).arrest and cell survival after DNA damage [42,43]. More-
over, TADA2A overexpression is pro-apoptotic in re-
sponse to DNA damage [44]. Thus, its deletion in GCTs
should provide resistance to apoptosis [45]. FOXO factorsSignaling 
p  0.0002 
Transcription 
regulation 
p  0.0002 
eted candidates drivers in adult-type GCTs. a. Hierarchical clustering
7 deleted candidate drivers (green), and FOXL2 in the 10 GCTs (see
group contains 5 deleted putative drivers together with the majority
lmost all amplified genes, and one broken and 1 deleted genes.
rate group along with the remaining broken gene. b. Physical
r deleted candidate drivers and common binding partners. Known
dinstitute.org/mpg/dapple/dappleTMP.php, see [48]), using default
ted hub position of AKT1 and the partition of identified binding
lysis was performed with Enrichr, for the 43 genes depicted in the
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mote cycle arrest and DNA damage repair, or apoptosis.
We have previously shown that FOXL2 is acetylated [46]
and that it upregulates stress-response genes and induces
cell-cycle slow-down [8]. A hyperlinked gene list with
more complete information is provided in Additional file
2: Table S2a and S2b.
Next, we identified genes recurrently broken in the
tumor samples. They were pinpointed by the existence, in
at least 2 tumors, of one or several closely mapping break-
points defined by amplifications/deletions upstream and
downstream, within the relevant gene. A literature search
for the 5 genes identified as broken showed that 4 of them
are clearly involved in cancer (Table 2, more details are
provided in Additional file 2: Table S2a and S2b). In par-
ticular, NPAS3 and RUNX1 are known tumor suppressors
and CELF4 is known to be frequently deleted in cancer.
Broken genes might be fusion partners, as described for
RUNX1 in leukaemia [47], although we have no direct evi-
dence for this.Figure 4 Sharing of transcriptional neighbors among amplified/delete
within a network with strongly correlated transcriptional neighbors (R > =0
diameter of the nodes reflects the number of neighbors. Amplified gen
high-resolution zoomable network is provided in Additional file 3: Figu
parallels the same groups of candidate drivers than the expressional co
in Figure 3a share many positive and negative neighbors, and those n
gene of this group, MMAB. The amplified genes of the second cluster (
to the dense sub-network of deleted candidate drivers restricted to C22orf26
only to neighbors of the first dense sub-network. Large grey nodes depict tra
candidate drivers (i.e. POU3F1, MCM9, RPL10, POLR1D, PCNA, POLA1, PI4KThe candidate drivers are expressionally clustered and
share transcriptomic neighbors
To explore possible functional links among the candidate
drivers, we performed a standard hierarchical clustering
of the expression levels of the 20 amplified/deleted candi-
date drivers, the 5 broken genes and FOXL2 (Figure 3A).
This analysis defined three main groups: group 1 con-
tained 6/7 deleted genes (i.e. NVL, RTF1, TADA2A,
HSPA4, FAM177A1, LIMA1), 3/5 broken genes (which is
coherent with a loss of function), 1 amplified gene
(MMAB) and FOXL2 itself; group 2 involved 11/13 ampli-
fied genes (including AKT1), 1 broken one and 1 deleted
gene (C19orf18); and group 3 involved 1 broken gene
(C8orf34) along with amplified TSPAN32. Functional
links between these genes are supported by their interac-
tions with common partners (Figure 3b), as detected by
Dapple2 for 11/25 genes [48].
To further explore the implication of amplified/deleted
candidate drivers in processes altered in cancer, we de-
termined for each of them a list of positive and negatived genes. The 20 putative drivers and FOXL2 (blue nodes) are depicted
,90), either positively (blue edges) or negatively (green edges). The
es are labeled with a red a, and deleted ones with a green d. A
re S1. Notice that extensive sharing of transcriptomic neighbors
rrelation in Figure 3a. Five of the deleted genes in the first group
eighbors are mainly negatively connected to the only amplified
from Figure 2a) are grouped in a distinct sub-network with a connection
and SPRYD3. Amplified TSPAN32 has a peculiar position, as it is connected
nscriptomic neighbors that are connected to a large portion of the
AP2).
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levels displayed R > =0.63 or R = <−0.63 with the expres-
sion of the relevant driver over the tumor samples). Such
transcriptomic (positive and negative) neighbors are
more likely to be functionally linked to the drivers than
random genes. A gene ontology analysis using EnrichR
[10] showed that the negative transcriptomic neighbors
of amplified drivers and the positive neighbors of deleted
drivers were enriched in keywords involving cell cycle,
suggesting a coherent effect of these two types of alter-
ations. Other enriched keywords pointed to different
types of cancer, DNA damage response, DNA repair and
regulation of ubiquitinylation during mitosis (Additional
file 2: Table S2c). Interestingly, all the candidate drivers
shared a statistically significant proportion of transcrip-
tomic neighbors. The network of Figure 4 (and Additional
file 3: Figure S1) shows several interesting points: i) 5
of the deleted genes (NVL, RTF1, TADA2A, HSPA4,
FAM177A1) included in group 1 share a highly significant
number of transcriptomic neighbors and form a dense
sub-network; ii) four amplified genes, MMAB, SPRYD3,
C22orf26 and TSPAN32 are anti-correlated with a large
number of positive neighbors of these 5 deleted putative
drivers; iii) the amplified genes included in the expression
group 2 also share transcriptomic neighbors and iv)
FOXL2 is heavily connected to the deleted putative
drivers, which suggests an interplay between the C134W
mutation and the genomic alterations (especially the dele-
tions) that we have detected.
Conclusions
In conclusion, our analysis identifies candidate co-driver
genes, whose various alterations could contribute to
GCT pathogenesis besides the FOXL2 somatic mutation.
This is strengthened by their high degree of expressional
interconnection, which suggests the existence of func-
tional interactions among them, and by their known or
suggested implication in cancer and related processes.
However, we are aware that, given the small sample size
for which CGH and transcriptomic data were available,
this genomic exploration only provides leads for func-
tional analyses to formally demonstrate the implication
of the candidate drivers in GC tumorigenesis.Additional files
Additional file 1: Table S1. Tab a – Rainbow overview of genomic
alterations in 10 adult ovarian GCTs. The CGH data is displayed as
averaged values for sliding 130 kb windows, in log2 scale. In that scale,
equivalent amount of genomic DNA for the tumor sample and the
control DNA is displayed as values around the baseline at 0, segments
below 0 indicate deletions, and segment above 0 indicate amplifications.
Each chromosome is depicted with a different color. Tab b – Details of
large-scale genomic alterations detected by CGH in the 10 GCTs. The clinical
details were previously published in [49]. The recurrent alterations areindicated in bold. Tab c – Details of large-scale genomic alterations
detected in ovarian GCTs by five different studies. The alterations are
listed by chromosome. Clinical details are indicated when available.
For each tumor, the alteration of the chromosome is written in black,
other rearrangements present in the same tumors are indicated in
grey and in parenthesis. Note that for acrocentric chromosomes, an
alteration of the q arm is indicative of the amplification or loss of
the whole chromosome (i.e. trisomy or monosomy). The last two columns
highlight the associated recurrent alterations, and indicate whether these
are statistically overrepresented (two-tailed p, Fisher’s exact test on a
contingency table).
Additional file 2: Table S2. Tab a – List of broken, amplified and
deleted candidate driver genes. This table is a more complete, detailed
and hyperlinked version of Tables 1 and 2. Genes altered by breakpoint
were identified by upstream and downstream rearranged CGH status in
at least 2 tumors. The breakpoint must be within the gene in all the
tumors, and not included in frequent CNVs detected in healthy control
samples. Candidate driver genes were identified as presenting an
expression significantly correlated (correlation coefficient >= 0.63) with
the CGH status, in at least 2 tumors, without being included in CNVs
detected in healthy control samples. CNVs were verified in DGV database,
that contains the genomic alterations involving segments of DNA that
are larger than >50bp identified in healthy control samples (DGV update:
31/05/2013). Tab b – Details of the genomic alterations leading to the
identification of broken genes in ovarian GCTs. For each breakpoint are
indicated: the tumors displaying an alteration, the genomic coordinates
of the alterations, the name of the broken gene, bibliographic data
centered on cancer-related processes, and the screenshot of the display
in MeV software. Bright red and green regions are genomic segments
respectively amplified or deleted in more than 50% of the cells in the
tumor samples. Tab c – Keywords enrichment of transcriptomic
neighbors lists for the 20 putative amplified/deleted drivers. For each
candidate driver, the sets of transcriptomic neighbors with a statistically
significant correlation of expression (R>= 0.63 or R<= −0.63) were tested
using Enrichr. The keywords in KEGG pathways and in Gene Ontology
Biological Process (GO-BP) are given for positive and negative neighbors,
when they reached significant enrichment after correction of the p-value by
the Bonferroni method. Cancer-related keywords are highlighted in red.
Additional file 3: Figure S1. High-resolution image of the network
between the 20 candidate drivers and their highly-correlated transcriptomic
neighbors. Blue nodes: 20 candidate drivers and FOXL2. Amplified genes
are labeled with a red a, and deleted ones with a green d. Grey nodes:
transcriptomic neighbors with expression correlated with a correlation
coefficient >= 0.90 to at least one of the candidate drivers or FOXL2.
The sizes of the node and of the node label are proportional to the
number of edges. Some transcriptomic neighbors are connected to a
large portion of the candidate drivers (large grey nodes). Purple
edge: positive correlation between the candidate driver (or FOXL2)
and its transcriptomic neighbor. Green edge: negative correlation between
the candidate driver (or FOXL2) and its transcriptomic neighbor. The edges
are rendered semi-transparent in order to keep the gene names visible. The
picture is zoomable to see individual gene names. The Cytoscape session
file is available upon request.
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